{
  "meta": {
    "title": "Malignant_Lesions",
    "url": "https://brainandscalpel.vercel.app/malignant-lesions-78e1b680.html",
    "scrapedAt": "2025-11-30T08:51:28.954Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Tubule formation</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Nuclear pleomorphism</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Lymphatic invasion</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Mitoses/HPF</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old woman presents with a firm, palpable mass in her left breast. Mammography shows a suspicious lesion, and core needle biopsy confirms ductal carcinoma in situ (DCIS). The pathology report also indicates a high mitotic rate and nuclear pleomorphism. Which of the following factors is NOT included in the Modified Bloom-Richardson grading system for breast carcinoma?</span></p>",
      "unique_key": "DT1296190",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296190,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Pathology of Breast Cancer</strong></p>\r\n<ul>\r\n<li>Origin: Most breast cancers arise from the <strong>milk ducts (90%)</strong> or the <strong>lobules (10%).</strong></li>\r\n<li><strong>In Situ vs. Invasive:</strong> Ductal or lobular carcinoma can remain in situ (confined to the epithelium with no breach in the basement membrane) or become invasive (infiltrating surrounding tissue through the basement membrane).</li>\r\n<li>Grading: Breast cancer is graded using the <strong>Modified Bloom-Richardson system:</strong>\r\n<ul>\r\n<li>Tubule formation: Percentage of tumor cells forming tubules.</li>\r\n<li>Nuclear pleomorphism: Degree of variation in the size and shape of tumor cell nuclei.</li>\r\n<li>Mitoses/HPF: Number of mitotic figures per high-power field.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Grading Scores:</strong></p>\r\n<p>Grade I (3-5 points): Well-differentiated</p>\r\n<p>Grade II (6-7 points): Moderately differentiated</p>\r\n<p>Grade III (8-9 points): Poorly differentiated</p>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Tubule formation - Correct. It is one of the three variables used in the Modified Bloom-Richardson system for grading breast carcinoma.</p>\r\n<p>Option B) Nuclear pleomorphism - Correct. Nuclear pleomorphism is part of the grading system and assesses the variation in size and shape of tumor cell nuclei.</p>\r\n<p>Option C) Lymphatic invasion - Incorrect. Lymphatic invasion is important for prognosis but is <strong>not included in the Modified Bloom-Richardson grading system.</strong></p>\r\n<p>Option D) Mitoses/HPF - Correct. This is one of the three variables used to determine tumor grade, based on the number of mitoses per high-power field.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>The Modified Bloom-Richardson score is the sum of three variables: tubule formation, nuclear pleomorphism, and mitoses.</p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Luminal A</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Luminal B</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">HER2/neu enriched</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Basal type</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old woman presents with a breast lump. Biopsy reveals invasive carcinoma. Immunohistochemistry shows the tumor is ER-positive, PR-positive, and HER2-negative, with a low Ki-67 index. What is the most likely molecular subtype of this carcinoma?</span></p>",
      "unique_key": "DT1296393",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296393,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Molecular Subtypes</strong>:</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501152dea21bb-536d-4a22-810b-46790444ce16.jpg\">\r\n<ul>\r\n<li>Ki-67 Index: Measures tumor proliferation rate; higher Ki-67 suggests more aggressive disease.</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Correct. Luminal A tumors are ER/PR positive, HER2-negative, and have a low Ki-67 index, which fits the patient's profile.</p>\r\n<p>Option B) Incorrect. Luminal B tumors are also ER/PR positive but have a high Ki-67 index, indicating more aggressive behavior.</p>\r\n<p>Option C) Incorrect. HER2/neu enriched tumors are HER2-positive.</p>\r\n<p>Option D) Incorrect. Basal-type tumors are typically triple-negative (ER/PR and HER2-negative) and have high Ki-67.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Luminal A is the most common and least aggressive subtype. Ki-67 is an important marker to differentiate between luminal A and B subtypes.</p>",
      "correct_choice_id": 11,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Neoadjuvant chemotherapy with hormonal therapy</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Neoadjuvant targeted therapy with trastuzumab and pertuzumab</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Surgery followed by adjuvant chemotherapy</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediate surgery with no neoadjuvant therapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old premenopausal woman with locally advanced breast cancer (T3N2M0) is being considered for surgery. Her oncologist recommends neoadjuvant systemic therapy (NAST) before the surgery. The tumor is HER2/neu-positive, and axillary node involvement is confirmed. Which of the following would be the most appropriate neoadjuvant therapy for this patient?</span></p>",
      "unique_key": "DT1296400",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296400,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Neoadjuvant Systemic Therapy (NAST)</strong></p>\r\n<ul>\r\n<li>Administered before surgery to downsize the tumour,</li>\r\n<li><strong>Indications for NACT:</strong>\r\n<ul>\r\n<li>Locally advanced breast cancer (T3, T4/N2, N3) to downsize the tumour.</li>\r\n<li>Selected early breast cancer cases, including HER2/neu-positive and triple-negative breast cancer (TNBC).</li>\r\n<li>Premenopausal women (&lt;50 years) or those with axillary node metastasis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Neoadjuvant Targeted Therapy:</strong>\r\n<ul>\r\n<li>HER2/neu-positive <strong>tumours &gt;5 mm</strong> are treated with <strong>trastuzumab</strong> and <strong>pertuzumab</strong> as neoadjuvant therapy.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Neoadjuvant Hormonal Therapy:</strong>\r\n<ul>\r\n<li>Reserved for elderly or frail women with ER/PR-positive tumours who are unfit for systemic chemotherapy. Takes 3-6 months for the response.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Response Assessment:</strong>\r\n<ul>\r\n<li>RECIST criteria are used to evaluate response after <strong>two cycles</strong> of neoadjuvant therapy.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Complete Response (CR):</strong> Lesion not detectable on clinical palpation and imaging.</li>\r\n<li><strong>Partial Response (PR):</strong> &ge;30% reduction in tumour size.</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Neoadjuvant chemotherapy with hormonal therapy: Incorrect. This patient is premenopausal and HER2/neu-positive, so targeted therapy is preferred.</p>\r\n<p>Option B) Neoadjuvant targeted therapy with trastuzumab and pertuzumab: Correct. HER2/neu-positive tumors &gt;5 mm, especially in the presence of axillary node involvement, benefit from neoadjuvant targeted therapy with trastuzumab and pertuzumab.</p>\r\n<p>Option C) Surgery followed by adjuvant chemotherapy: Incorrect. Surgery followed by adjuvant chemotherapy is not the recommended approach in locally advanced disease (T3N2) when neoadjuvant therapy could downsize the tumor before surgery.</p>\r\n<p>Option D) Immediate surgery with no neoadjuvant therapy: Incorrect. Immediate surgery without neoadjuvant therapy is not appropriate in locally advanced breast cancer.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>HER2/neu-positive patients benefit from neoadjuvant targeted therapy (trastuzumab and pertuzumab).</p>",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Breast-conserving surgery (BCS)</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Radical mastectomy (Halsted)</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Modified radical mastectomy (MRM)</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Simple mastectomy without lymph node dissection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman presents with a large mass in her left breast. Mammography reveals diffuse microcalcifications consistent with ductal carcinoma in situ (DCIS) and a BRCA1 mutation is confirmed. After discussing treatment options, the patient opts for surgery. What is the most appropriate surgical treatment for this patient?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250115edf0e6b7-e29b-4bcb-9e7e-c79d8d65624a.jpg\"></span></p>",
      "unique_key": "DT1296405",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296405,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Mastectomy Indications and Types</strong></p>\r\n<ul>\r\n<li><strong>Indications for Mastectomy:</strong>\r\n<ul>\r\n<li>Large tumors relative to breast size, multicentric disease, diffuse microcalcifications, BRCA mutations, recurrence after breast-conserving surgery, and patient preference.</li>\r\n</ul>\r\n</li>\r\n<li>Types of Mastectomy:\r\n<ul>\r\n<li><strong>Simple Mastectomy:</strong> Removal of breast tissue without axillary dissection.</li>\r\n<li><strong>Modified Radical Mastectomy (MRM):</strong> Removal of breast tissue and axillary lymph nodes (levels I, II, III).</li>\r\n<li><strong>Radical Mastectomy (Halsted):</strong> Removal of breast tissue, pectoralis muscles, and axillary lymph nodes; rarely performed due to high morbidity.</li>\r\n</ul>\r\n</li>\r\n<li>Complications of Radical Mastectomy: Shoulder movement limitation, extensive upper limb lymphedema, pain, chest wall deformity.</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. BCS would not be appropriate for diffuse microcalcifications indicative of DCIS, or for BRCA1-positive patients, as the risk of recurrence is higher.</p>\r\n<p>Option B) Incorrect. <strong>Radical mastectomy (Halsted) involves the removal of breast tissue, pectoralis muscles, and all axillary nodes.</strong></p>\r\n<p>Option C) Correct. Modified radical mastectomy (MRM) is the appropriate treatment, as it involves mastectomy along with <strong>axillary lymph node dissection (levels I, II, and III),</strong> making it suitable for large tumors, multicentric disease, or genetic predisposition (BRCA mutations).</p>\r\n<p>Option D) Incorrect. <strong>Simple mastectomy</strong> without lymph node dissection is inadequate for patients with <strong>DCIS and BRCA1 mutations</strong>, as axillary lymph node evaluation is essential.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Modified radical mastectomy is preferred over radical mastectomy due to fewer complications and no difference in survival benefit.</p>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">The tumor is located in the upper outer quadrant of the breast.</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">The tumor is 2 cm away from the skin.</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">The patient has diffuse microcalcifications on a mammogram.</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">The tumor is >2 cm away from the nipple.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old female with a diagnosis of ductal carcinoma in situ (DCIS) in the upper outer quadrant of the left breast is being evaluated for surgical treatment. The tumour is 2 cm in size and is located 3 cm from the nipple and 2 cm from the skin. She is concerned about the cosmetic outcome post-surgery. Her oncologist suggests either a skin-sparing mastectomy with immediate reconstruction or breast-conserving surgery (BCS). Which of the following factors would make this patient a poor candidate for breast conservation surgery (BCS)?</span></p>",
      "unique_key": "DT1296414",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296414,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Breast Conservation Surgery (BCS)</strong></p>\r\n<ul>\r\n<li><strong>Skin-and Nipple-Sparing Mastectomy:</strong>\r\n<ul>\r\n<li>Suitable for DCIS and early breast cancers where the <strong>tumour is &gt;1 cm away from the skin and &gt;2 cm away from the nipple</strong>. Reconstruction can be done using autologous tissue or silicone implants.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Breast Conservation Surgery (BCS):</strong>\r\n<ul>\r\n<li>Aimed at removing <strong>the tumor with a 1 cm margin of normal breast tissue.</strong> Post-surgery, all patients receive <strong>radiotherapy (RT).</strong> BCS combined with RT is called breast conservation therapy (BCT).</li>\r\n</ul>\r\n</li>\r\n<li><strong>Wide Local Excision (WLE):</strong> Up to 20% of breast tissue can be removed with WLE. Oncoplastic surgery may be required for volume loss greater than 20% to maintain breast shape and symmetry.</li>\r\n<li><strong>Contraindications to BCS:</strong>\r\n<ul>\r\n<li><strong>Multicentric tumours.</strong></li>\r\n<li><strong>Diffuse microcalcifications on mammogram.</strong></li>\r\n<li><strong>Large tumour-to-breast ratio.</strong></li>\r\n<li><strong>History of previous breast or chest wall radiation.</strong></li>\r\n<li><strong>Collagen vascular diseases (e.g., SLE).</strong></li>\r\n<li><strong>Severe orthopnea (unable to lie flat for radiotherapy)</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. The location of the tumour in the upper outer quadrant does not preclude the option of breast conservation surgery.</p>\r\n<p>Option B) Incorrect. A tumour distance of 2 cm from the skin is acceptable for breast conservation surgery.</p>\r\n<p>Option C) Correct. Diffuse microcalcifications on a mammogram are a contraindication for breast conservation surgery due to the difficulty in achieving clear margins.</p>\r\n<p>Option D) Incorrect. A tumour that is &gt;2 cm away from the nipple is not a contraindication to breast conservation surgery.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Margins: A: 1-cm margin is required for BCS. Radiotherapy: All patients undergoing BCS must receive radiotherapy.</p>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Modified radical mastectomy</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Simple mastectomy</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Wide local excision (WLE)</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Skin-sparing mastectomy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman with early-stage breast cancer presents to discuss surgical options. She is interested in preserving her breast as much as possible but is also concerned about recurrence and wants to understand her choices for removing the tumour with clear margins. Which of the following procedures would most likely offer the patient breast conservation while achieving tumour-free margins with adequate cosmetic outcomes?</span></p>",
      "unique_key": "DT1296461",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296461,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Surgical Techniques for Breast Cancer</strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250115d8681189-61d8-43e4-b79b-5afa5234067f.jpg\">\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Modified radical mastectomy: Involves removal of the entire breast and axillary lymph nodes (levels I, II, and III). It is not a breast-conserving surgery and is used in cases requiring extensive tissue removal.</p>\r\n<p>Option B) <strong>Simple mastectomy: Also called total mastectomy</strong>, it involves <strong>removal of the breast without lymph node dissection or preservation of breast tissue</strong>. It does not conserve breast tissue.</p>\r\n<p>Option C) <strong>Wide local excision (WLE): Also known as lumpectomy or breast-conserving surgery</strong> (BCS). It involves removing the tumor with a margin of healthy tissue around it, while preserving the rest of the breast, making it the best option for patients wanting breast conservation.</p>\r\n<p>Option D) Skin-sparing mastectomy: Removes breast tissue but preserves the skin envelope for reconstruction. While preserving the skin, it is not considered a breast-conserving surgery like WLE.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>WLE is the preferred option for breast conservation, particularly in early-stage cancers. Modified radical mastectomy is used when more extensive tissue removal is required, but it is not a conserving surgery.</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">No further treatment needed</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Adjuvant chemotherapy followed by radiotherapy</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Radiotherapy only to the chest wall</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Radiotherapy to the whole breast</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old woman presents with T2N1M0 invasive ductal carcinoma of the breast and undergoes breast-conserving surgery (BCS). The surgical margins are clear with no lymphovascular invasion (LVI). The tumor is estrogen receptor-positive, and sentinel lymph nodes are negative. Which of the following is the most appropriate next step in management?</span></p>",
      "unique_key": "DT1296467",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296467,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Radiotherapy in Breast Cancer</strong></p>\r\n<ul>\r\n<li>Indications for Radiotherapy:\r\n<ul>\r\n<li>After Breast-Conserving Surgery (BCS).</li>\r\n<li>For locally advanced cancers (T3, T4, N1-N3).</li>\r\n<li>After mastectomy for tumors&ge;5 cm, LVI, or lymph node involvement.</li>\r\n</ul>\r\n</li>\r\n<li>Post-BCS Radiotherapy:\r\n<ul>\r\n<li>Dose: 45-50.4 Gy (in 25 fractions) or 40-42.5 Gy (hypofractionation in 15-16 fractions).</li>\r\n<li>Purpose: Decreases locoregional and systemic recurrence.</li>\r\n</ul>\r\n</li>\r\n<li>Post-Mastectomy Radiotherapy:\r\n<ul>\r\n<li>Given for T3N0M0 disease when <strong>sentinel nodes are negative.</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Lymph node-positive disease:</strong> Radiotherapy to chest wall, supraclavicular region, internal mammary nodes, and axilla (if no axillary node dissection).</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. No further treatment is not appropriate as radiotherapy is typically recommended after BCS to reduce locoregional recurrence.</p>\r\n<p>Option B) Incorrect. Chemotherapy may be considered depending on tumor biology, but in this case, the clear margins and negative LVI do not indicate its immediate necessity. However, radiotherapy remains a mainstay after BCS.</p>\r\n<p>Option C) Incorrect. Radiotherapy to the chest wall is generally reserved for post-mastectomy patients or those with chest wall involvement.</p>\r\n<p>Option D) Correct. Whole-breast <strong>radiotherapy</strong> is the standard treatment <strong>following BCS</strong> to prevent local recurrence, especially in cases with T2 disease.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Radiotherapy is essential after BCS to prevent locoregional recurrence. Post-mastectomy radiotherapy is indicated for tumors &ge;5 cm or node-positive disease.</p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Taxane-based chemotherapy only</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Trastuzumab + Pertuzumab along with Taxane + Anthracycline</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Anthracycline-based chemotherapy (CAF: Cyclophosphamide, Adriamycin, 5-Fluorouracil)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old female is diagnosed with invasive ductal carcinoma of the breast. The tumor measures 1.2 cm in diameter, is HER2/neu-positive, and has no lymph node involvement. The oncologist is considering systemic treatment options. Which of the following chemotherapy regimens is most appropriate for this patient?</span></p>",
      "unique_key": "DT1296471",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296471,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Chemotherapy in Breast Cancer</strong></p>\r\n<ul>\r\n<li>Chemotherapy Regimens:\r\n<ul>\r\n<li><strong>CMF:</strong> Cyclophosphamide, Methotrexate, 5-Fluorouracil.</li>\r\n<li>Anthracycline-based: <strong>CAF</strong> (Cyclophosphamide, Adriamycin [Doxorubicin], 5-Fluorouracil), CEF (Cyclophosphamide, Epirubicin, 5-Fluorouracil).</li>\r\n<li><strong>Taxane-based:</strong> Docetaxel, Paclitaxel.</li>\r\n<li><strong>Trastuzumab + Pertuzumab:</strong> Targeted therapy for HER2/neu-positive tumors, combined with taxane + anthracycline.</li>\r\n</ul>\r\n</li>\r\n<li>Indications for Adjuvant Chemotherapy:\r\n<ul>\r\n<li>Tumours &gt;1 cm or &gt;0.5 cm with poor prognostic factors <strong>(e.g., lymphovascular invasion [LVI], HER2/neu-positive, high grade, triple-negative breast cancer [TNBC], node-positive).</strong></li>\r\n</ul>\r\n</li>\r\n<li>Gene Signature Panels:</li>\r\n<li>Oncotype Dx&reg;: Used to calculate risk of recurrence (ROR) scores for ER-positive, HER2/neu-negative, node-negative tumors.\r\n<ul>\r\n<li><strong>Low ROR (&lt;18) means chemotherapy can be avoided. High ROR (&gt;30) indicates benefit from chemotherapy.</strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. The CMF regimen (Cyclophosphamide, Methotrexate, 5-Fluorouracil) is used but not the first-line option for HER2/neu-positive tumors.</p>\r\n<p>Option B) Incorrect. Taxane-based chemotherapy alone is not sufficient for HER2/neu-positive patients.</p>\r\n<p>Option C) Correct. HER2/neu-positive breast cancer patients should receive trastuzumab + pertuzumab along with taxane and anthracycline-based chemotherapy to target the HER2 protein and improve outcomes.</p>\r\n<p>Option D) Incorrect. Anthracycline-based chemotherapy (CAF) may be used, but the addition of trastuzumab and pertuzumab is crucial for HER2/neu-positive tumors.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<ul>\r\n<li><strong>Luminal A:</strong> May avoid chemotherapy if low-risk score.</li>\r\n<li><strong>Luminal B:</strong> Anthracycline and/or taxane-based chemotherapy.</li>\r\n<li><strong>HER2/neu-positive:</strong> Trastuzumab + Pertuzumab + chemotherapy (taxane + anthracycline).</li>\r\n<li><strong>Triple-negative breast cancer:</strong> Taxane + anthracycline. Carboplatin may be beneficial for aggressive tumors.</li>\r\n</ul>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Aromatase inhibitor for 5 years</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Tamoxifen for 10 years</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Aromatase inhibitor for 10 years</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">No hormonal therapy required</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old premenopausal woman with a history of invasive breast cancer, 4 cm in size and node-positive, is being considered for adjuvant therapy following surgery. Her oncologist recommends hormonal therapy. Which of the following would be the most appropriate hormonal therapy in this patient?</span></p>",
      "unique_key": "DT1296473",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296473,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Hormonal Therapy in Breast Cancer</strong></p>\r\n<ul>\r\n<li><strong>Tamoxifen:</strong>\r\n<ul>\r\n<li>Selective estrogen receptor modulator (SERM) used in premenopausal women for <strong>5 years in low-risk and 10 years in high-risk patients</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Aromatase Inhibitors (Anastrozole, Letrozole, Exemestane):</strong>\r\n<ul>\r\n<li>Used in postmenopausal women. More effective than tamoxifen in relapse-free survival but associated with bone density loss.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management of Bone Loss:</strong>\r\n<ul>\r\n<li>Bisphosphonates, vitamin D, and calcium supplements are advised to prevent fractures and bone loss.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p>Explanation of Options:</p>\r\n<p>Option A) Incorrect. Aromatase inhibitors are typically used in postmenopausal women, not premenopausal women.</p>\r\n<p>Option B) Correct. <strong>Tamoxifen</strong> is the recommended hormonal therapy in <strong>premenopausal women with high-risk breast cancer</strong></p>\r\n<p>Option C) Incorrect. <strong>Aromatase inhibitors are not used in premenopausal women</strong>.</p>\r\n<p>Option D) Incorrect. Hormonal therapy is crucial in reducing the risk of relapse in hormone receptor-positive breast cancer.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Tamoxifen is used in premenopausal women. Aromatase inhibitors are preferred in postmenopausal women but cause bone density loss.</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">The patient's age at diagnosis of TNBC (&le;60 years)</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Absence of a family history of other cancers</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">TNBC is not a high-risk subtype for genetic mutations</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Genetic testing is unnecessary unless there are multiple family members with cancer</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman is diagnosed with triple-negative breast cancer (TNBC). Which of the following most accurately indicates the need for genetic risk evaluation in this patient?</span></p>",
      "unique_key": "DT1296477",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296477,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025011512e9455b-33a7-47b5-8a69-30324f297d38.jpg\">\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Correct: A diagnosis of triple-negative breast cancer (TNBC) at age &le;60 years is a strong indication for genetic risk evaluation, regardless of other family history.</p>\r\n<p>Option B) Incorrect: Although family history can further elevate risk, the patient's age and subtype of breast cancer (TNBC) are already sufficient indicators for genetic testing.</p>\r\n<p>Option C) Incorrect: TNBC is a high-risk subtype often associated with BRCA1/2 mutations and other hereditary cancer syndromes, particularly in younger patients.</p>\r\n<p>Option D) Incorrect: Multiple family members with cancer increase risk, but this patient's young age and TNBC diagnosis alone warrant genetic testing.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Early diagnosis of TNBC (age &le;60) is a key indicator for genetic evaluation. Family history of breast, ovarian, and other cancers strengthens the need for testing.</p>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Wide local excision</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Mastectomy with a portion of the pectoralis major muscle and radiotherapy</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Chemotherapy followed by observation</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Observation without intervention</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old male presents with a painless subareolar lump that has gradually increased in size over the past few months. There is also involvement of the nipple and areolar complex. What is the best treatment for this patient?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025011563f48cb8-ed32-4044-8c82-d9b105cc2c40.jpg\"></span></p>",
      "unique_key": "DT1296479",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296479,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Carcinoma of the Male Breast</strong></p>\r\n<ul>\r\n<li>Epidemiology: Male breast cancer is rare, accounting for <strong>less than 0.5% of breast cancer</strong></li>\r\n<li><strong>Presentation:</strong> Typically presents with a painless subareolar lump. Involvement of the nipple-areolar complex and underlying pectoral muscles occurs early.</li>\r\n<li>Treatment: Standard treatment includes <strong>mastectomy with a 2-cm margin and removal of a portion of the pectoralis major muscl</strong> Radiotherapy is recommended post-surgery. Sentinel lymph node biopsy (SLNB) should be performed in node-negative patients.</li>\r\n<li><strong>Tamoxifen:</strong> Recommended for patients with ER-positive tumors (20 mg daily for 5 years).</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. Wide local excision is not the standard treatment for male breast cancer with early nipple-areolar complex involvement.</p>\r\n<p>Option B) Correct. Mastectomy with a portion of the pectoralis major muscle, followed by radiotherapy, is the standard treatment for male breast cancer involving the nipple and areolar complex. Sentinel lymph node biopsy should also be performed in node-negative patients.</p>\r\n<p>Option C) Incorrect. Chemotherapy is reserved for advanced or metastatic cases.</p>\r\n<p>Option D) Incorrect. Observation without intervention is not recommended for breast cancer.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Male breast cancer often presents with subareolar lumps and early nipple involvement. The standard treatment is mastectomy with radiotherapy.</p>",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Prior radiotherapy</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">BRCA1 mutation</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Family history of breast cancer</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Exposure to benzene</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 40-year-old woman presents with a rapidly enlarging breast mass. A biopsy confirms angiosarcoma. Which of the following is most likely associated with the development of this tumor?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250115419ae304-ed77-4148-ae86-1710c0904d5f.jpg\"></span></p>",
      "unique_key": "DT1296480",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296480,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Sarcoma of the Breast</strong></p>\r\n<ul>\r\n<li>Sarcomas arise from <strong>mesenchymal tissues in the breast</strong>, with the most common types being fibrosarcoma and angiosarcoma.</li>\r\n<li><strong>Angiosarcoma: The most aggressive of all breast tumors</strong>, arising from the endothelial cells of blood or lymphatic channels. It has a poor prognosis.</li>\r\n<li><strong>Risk Factors:</strong>\r\n<ul>\r\n<li>Prior radiotherapy, chronic lymphoedema, and genetic conditions like Li-Fraumeni syndrome are associated with sarcoma development.</li>\r\n</ul>\r\n</li>\r\n<li>Prognosis: Angiosarcoma has a very poor prognosis and tends to metastasize early.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501158ef42f74-5bcf-43aa-946c-246db8f6e7b5.jpg\">\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Correct. Angiosarcoma is a rare and aggressive tumor arising from the endothelial cells of blood or lymphatic vessels and is associated with prior radiotherapy (e.g., for Hodgkin's lymphoma).</p>\r\n<p>Option B) Incorrect. BRCA1 mutation is associated with epithelial tumors like ductal or lobular carcinoma, not sarcoma.</p>\r\n<p>Option C) Incorrect. Family history is more commonly associated with epithelial cancers.</p>\r\n<p>Option D) Incorrect. Exposure to benzene is associated with hematologic malignancies, not sarcomas.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Angiosarcoma is the most aggressive breast sarcoma and is associated with prior radiotherapy.</p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">T2</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">T3</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">T4b</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">T4a</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman is diagnosed with breast cancer. Examination reveals ulceration of the skin over the tumour and extension to the chest wall. What is the TNM staging for this presentation?</span></p>",
      "unique_key": "DT1296481",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296481,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>TNM Staging for Breast Cancer</strong></p>\r\n<ul>\r\n<li>T Category (Primary Tumour)\r\n<ul>\r\n<li>Tx: Tumour cannot be assessed.</li>\r\n<li>T0: No evidence of primary tumour.</li>\r\n<li>Tis: In situ (DCIS or Paget&rsquo;s).</li>\r\n</ul>\r\n</li>\r\n<li>T1: Tumour &le;20 mm.\r\n<ul>\r\n<li>T1mi: &le;1 mm</li>\r\n<li>T1a: &gt;1 mm but &le;5 mm</li>\r\n<li>T1b: &gt;5 mm but &le;10 mm</li>\r\n<li>T1c: &gt;10 mm but &le;20 mm</li>\r\n</ul>\r\n</li>\r\n<li>T2: Tumour &gt;20 mm but &le;50 mm.</li>\r\n<li>T3: Tumour &gt;50 mm.</li>\r\n<li>T4: Tumour of any size with direct extension to chest wall/skin.\r\n<ul>\r\n<li>T4a: Chest wall invasion.</li>\r\n<li>T4b: Ulceration, nodules, or edema (peau d'orange).</li>\r\n<li>T4c: Combination of T4a and T4b.</li>\r\n<li>T4d: Inflammatory carcinoma.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<ul>\r\n<li>N Category (Regional Lymph Nodes)\r\n<ul>\r\n<li>Nx: Regional nodes cannot be assessed.</li>\r\n<li>N0: No metastases.</li>\r\n<li>N1: Metastases to movable ipsilateral level I/II nodes.\r\n<ul>\r\n<li>N1mi: Micrometastases (0.2-2 mm).</li>\r\n</ul>\r\n</li>\r\n<li>N2: Fixed/matted axillary or internal mammary nodes.\r\n<ul>\r\n<li>N2a: Fixed axillary nodes.</li>\r\n<li>N2b: Only internal mammary nodes.</li>\r\n</ul>\r\n</li>\r\n<li>N3: Metastases in infraclavicular, internal mammary, or supraclavicular nodes.\r\n<ul>\r\n<li>N3a: Infraclavicular nodes.</li>\r\n<li>N3b: Internal mammary and axillary nodes.</li>\r\n<li>N3c: Supraclavicular nodes.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<ul>\r\n<li>M Category (Distant Metastasis)\r\n<ul>\r\n<li>M0: No distant metastasis.</li>\r\n<li>M0(i+): Microscopic deposits &lt;0.2 mm in blood, bone marrow, or non-regional nodes.</li>\r\n<li>M1: Distant metastases.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. T2 refers to a tumor between 2 and 5 cm without skin or chest wall invasion.</p>\r\n<p>Option B) Incorrect. T3 refers to a tumor larger than 5 cm without skin or chest wall invasion.</p>\r\n<p>Option C) Correct. T4b: Ulceration and/or macroscopic satellite nodules and/or edema of the skin that does not meet the criteria for inflammatory carcinoma.</p>\r\n<p>Option D) Incorrect. T4a refers to a tumor of any size with direct extension to the chest wall</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>T4 tumors involve direct extension to the chest wall and/or skin. Inflammatory breast cancer (T4d) is associated with poor prognosis.</p>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Mastitis</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Paget's disease of the breast</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Inflammatory breast cancer</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Phyllodes tumor</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman presents with redness, swelling, and warmth of her left breast. The symptoms developed over a few weeks, and she noticed a peau d'orange appearance but no distinct lump. A core biopsy shows invasive ductal lesions. What is the most likely diagnosis?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250115e0b89477-2929-48f9-a893-748457f04cf6.jpg\"></span></p>",
      "unique_key": "DT1296482",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296482,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Inflammatory Breast Cancer (IBC)</strong></p>\r\n<ul>\r\n<li>Inflammatory carcinoma: peau d'orange and <strong>redness involving &gt;1/3rd of the surface of the breast with or without a breast lump</strong></li>\r\n<li>Pathology: Inflammatory breast cancer involves dermal lymphatic invasion, leading to rapid onset of erythema, warmth, and edema of the breast without a discrete lump.</li>\r\n<li>Diagnosis: Primarily clinical; confirmed by biopsy showing carcinoma cells in the dermal lymphatics.</li>\r\n<li>Imaging: Mammography may show skin thickening, but <strong>no mass may be present.</strong></li>\r\n<li>Treatment: Multimodality approach-neoadjuvant chemotherapy, mastectomy, and radiation. Trastuzumab for HER2-positive tumors; endocrine therapy for ER-positive tumors.</li>\r\n<li>Prognosis: <strong>Poorer compared to other breast cancers due to its aggressive nature.</strong> Relapse-free survival is about 50% with aggressive treatment.</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. Mastitis presents with similar inflammatory signs but is often associated with breastfeeding and infection. It typically responds to antibiotics, unlike IBC.</p>\r\n<p>Option B) Incorrect. Paget's disease is primarily characterised by eczematous changes around the nipple, not by breast swelling or redness.</p>\r\n<p>Option C) Correct. <strong>Inflammatory breast cancer</strong> is characterised by rapid onset of erythema, warmth, and edema, often without a palpable mass. The hallmark is the involvement of the dermal lymphatics, <strong>causing the peau d'orange appearance.</strong></p>\r\n<p>Option D) Incorrect. Phyllodes tumor is a rare breast tumor that typically presents as a <strong>fast-growing palpable mass without inflammatory symptoms.</strong></p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>Rapid onset of inflammatory symptoms is the hallmark of IBC. Sentinel lymph node biopsy is not indicated; axillary lymph node dissection is the standard.</p>",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Blue dye is injected into the tumor to guide the dissection.</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Axillary lymph node dissection should always be performed in addition to SLND.</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">SLND is less accurate after chemotherapy.</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">The combination of blue dye and radiotracer is used to improve detection rates.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old woman with T1 breast cancer is scheduled for breast-conserving surgery. The surgeon plans to perform a sentinel lymph node dissection. Which of the following statements about SLND is true?</span></p>",
      "unique_key": "DT1296484",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296484,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Sentinel Lymph Node Dissection (SLND)</strong></p>\r\n<ul>\r\n<li><strong>Purpose:</strong> SLND is a minimally invasive technique used to stage the axilla in breast cancer patients. It accurately identifies the sentinel node, which is the <strong>first lymph node to receive drainage from the tumour.</strong></li>\r\n<li>Technique: Involves the use of a radiotracer (<strong>usually 99mTc-labelled sulfur colloid</strong>) and <strong>blue dye (isosulfan blue)</strong> to identify the sentinel node(s).</li>\r\n<li>Indications: SLND is indicated for staging in early-stage breast cancer and to minimize morbidity compared to ALND.</li>\r\n<li>Outcomes: SLND has fewer complications than ALND, such as lymphedema, numbness, and shoulder stiffness.</li>\r\n<li>SLNB is contraindicated in patients with inflammatory breast cancer and in those with T4 disease or a history of previous breast or chest wall surgery, breast scarring (burns) or radiotherapy.</li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. Blue dye is injected peritumoral or subdermally, not into the tumour directly.</p>\r\n<p>Option B) Incorrect. Axillary lymph node dissection (ALND) is not always necessary after SLND, especially if the sentinel nodes are negative for metastasis.</p>\r\n<p>Option C) Incorrect. SLND remains accurate even after chemotherapy, though there may be a slightly higher false-negative rate.</p>\r\n<p>Option D) Correct. The combination of blue dye and radiotracer provides the lowest false-negative rate and helps localize the sentinel lymph node more effectively.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>SLND is accurate and has a lower morbidity than ALND. Blue dye and radiotracer combination improves sentinel node detection rates.</p>",
      "correct_choice_id": 144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Superior boundary: Second rib; Inferior boundary: Fifth rib</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Superior boundary: Clavicle; Inferior boundary: Inframammary fold</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Medial boundary: Lateral border of the sternum; Lateral boundary: Anterior axillary line</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Superior boundary: Pectoralis major; Inferior boundary: Costal margin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old woman diagnosed with invasive ductal carcinoma of the breast is scheduled for a modified radical mastectomy (MRM). Which of the following correctly describes the boundaries of resection in a modified radical mastectomy?</span></p>",
      "unique_key": "DT1296487",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296487,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Modified Radical Mastectomy (MRM)</strong></p>\r\n<ul>\r\n<li>Removal of the entire breast tissue along with level I and II axillary lymph nodes, sparing the pectoralis major muscle.\r\n<ul>\r\n<li>Boundaries of Resection:\r\n<ul>\r\n<li>Superior: Clavicle</li>\r\n<li>Inferior: Inframammary fold</li>\r\n<li>Medial: Lateral border of the sternum</li>\r\n<li>Lateral: Midaxillary line</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li>pectoralis minor muscle is removed in <strong>Patey/Madden</strong></li>\r\n<li>retracted in <strong>Auchincloss</strong> and is divided but not removed in <strong>Scanlon modifications</strong></li>\r\n<li>Complications: Lymphedema, shoulder stiffness, and risk of recurrence.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250115a204d482-ebc8-443f-a7de-1d2827d2ceb7.jpg\">\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. The superior boundary in modified radical mastectomy is the clavicle, not the second rib.</p>\r\n<p>Option B) Correct.</p>\r\n<p>Option C) Incorrect. The lateral boundary extends beyond the anterior axillary line to the midaxillary line for complete lymph node clearance.</p>\r\n<p>Option D) Incorrect. The costal margin is not a relevant boundary in breast surgery, and the pectoralis major is not removed in MRM.</p>\r\n<p><strong>Key Points</strong>:</p>\r\n<p>Modified radical mastectomy preserves the pectoralis major while ensuring complete removal of the breast and axillary lymph nodes.</p>",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Both BRCA1 and BRCA2 mutations increase the risk of breast cancer, but BRCA2 is more commonly associated with ovarian cancer.</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">BRCA1 mutations are associated with a higher risk of triple-negative breast cancer compared to BRCA2 mutations.</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">BRCA2 mutations are not associated with male breast cancer, while BRCA1 mutations are.</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">BRCA1 mutations are less likely to be involved in hereditary breast and ovarian cancer syndromes.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old woman with a family history of breast and ovarian cancer presents for genetic counselling. Her mother had breast cancer at the age of 45, and her aunt died from ovarian cancer. Genetic testing reveals a mutation in the BRCA1 gene. The patient is concerned about her risk for various cancers. Which of the following is true regarding BRCA1 and BRCA2 mutations?</span></p>",
      "unique_key": "DT1296490",
      "question_audio": null,
      "question_video": null,
      "map_id": 1296490,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Hereditary Breast Cancer (HBC):</strong></p>\r\n<ul>\r\n<li>Accounts for 5-10% of all breast cancers.</li>\r\n<li>Caused by identifiable genetic mutations like BRCA1, BRCA2, and others.</li>\r\n<li>More aggressive, presents earlier, often multicentric and bilateral.</li>\r\n</ul>\r\n<p><strong>Familial Breast Cancer (FBC):</strong></p>\r\n<ul>\r\n<li>Accounts for 20-30% of all breast cancers.</li>\r\n<li>Not associated with known genetic mutations but affects multiple family members.</li>\r\n</ul>\r\n<p><strong>BRCA1 (17q21):</strong></p>\r\n<ul>\r\n<li>50-85% lifetime risk of breast cancer.</li>\r\n<li>40% risk of ovarian cancer.</li>\r\n<li>Associated with triple-negative breast cancer (TNBC).</li>\r\n</ul>\r\n<p><strong>BRCA2 (13q12.3):</strong></p>\r\n<ul>\r\n<li>50-60% lifetime risk of breast cancer.</li>\r\n<li>20% risk of ovarian cancer.</li>\r\n<li>Associated with cancers of the <strong>prostate, colon, gallbladder, bile duct, stomach, and pancreas.</strong></li>\r\n</ul>\r\n<p>Risk-Reduction Options</p>\r\n<ul>\r\n<li><strong>Bilateral risk-reducing mastectomy:</strong></li>\r\n<li><strong>Reduces the risk of breast cancer by 90%.</strong></li>\r\n<li>Bilateral salpingo-oophorectomy:Offered to premenopausal women (after family completion) between 35-40 years</li>\r\n</ul>\r\n<p>Chemoprophylaxis:</p>\r\n<ul>\r\n<li><strong>Tamoxifen or Anastrozole can reduce breast cancer risk by 50%.</strong></li>\r\n</ul>\r\n<p><strong>Explanation of Options:</strong></p>\r\n<p>Option A) Incorrect. Both BRCA1 and BRCA2 mutations increase the risk of ovarian cancer, but BRCA1 mutations are more strongly associated with ovarian cancer compared to BRCA2.</p>\r\n<p>Option B) Correct. BRCA1 mutations are associated with a higher risk of developing triple-negative breast cancer, an aggressive subtype of breast cancer.</p>\r\n<p>Option C) Incorrect. BRCA2 mutations are indeed associated with male breast cancer, unlike BRCA1 mutations, which have a lower association.</p>\r\n<p>Option D) Incorrect. Both BRCA1 and BRCA2 are commonly involved in hereditary breast and ovarian cancer syndromes, but BRCA1 mutations are more strongly linked to ovarian cancer.</p>\r\n<p><strong>Key Points:</strong></p>\r\n<ul>\r\n<li>BRCA1: Strongly associated with triple-negative breast cancer and ovarian cancer.</li>\r\n<li>BRCA2: Higher association with male breast cancer and a broader range of other cancers.</li>\r\n</ul>",
      "correct_choice_id": 162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}